CD33 and acute myeloid leukemia: CD33+CD44+ AML cells are viable andexpand from 7% at day 0 to >10% at day 70 of culture, and theyrearrangethe typical leukemic niche within organoids, including expressionof fibronectin, VCAM-1, and N-Cadherin, surrounded by Osteopontin-and Osterix-expressing cells. Moreover,AML cells from day 70 organoids retain the ability to re-expand andform secondary organoids with long-term culture properties.